FDA approves Lilly's mAb to prevent migraine

Eli Lilly and Co. (NYSE:LLY) said FDA approved Emgality galcanezumab-gnlm to prevent migraine in adults. The mAb against calcitonin-related gene peptide (CGRP) is the third in its class that FDA has approved.

Lilly said Emgality will be available shortly, at a wholesale acquisition cost (WAC) of $575 monthly, or $6,900 annually. That price is at parity with the other two approved anti-CGRP mAbs: Ajovy fremanezumab-vfrm from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) and Aimovig erenumab-aooe from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN)...